Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Takahiro Nakayama¹, Naoki Niikura², Takashi Yamanaka³, Mitsugu Yamamoto⁴, Kazuo Matsuura⁵, Kenichi Inoue⁶, Sachiko Takahara⁷, Hironori Nomura⁸, Shosuke Kita⁹, Miki Yamaguchi¹⁰, Tomoyuki Aruga¹¹, Nobuhiro Shibata¹², Akihiko Shimomura¹³, Yuri Ozaki¹⁴, Shuji Sakai¹⁵, Daisuke Takiguchi¹⁶, Takehiko Takata¹⁶, Armin Bastanfard¹⁶, Kazuhito Shiosakai¹⁷, Junji Tsurutani¹⁸

Affiliations

¹ Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
² Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.
³ Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
⁴ Department of Breast Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
⁵ Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
⁶ Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
⁷ Department of Breast Surgery, Kitano Hospital, Osaka, Japan.
⁸ First Department of Surgery, University of the Ryukyus Hospital, Okinawa, Japan.
⁹ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
¹⁰ Department of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
¹¹ Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
¹² Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
¹³ Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
¹⁴ Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan.
¹⁵ Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
¹⁶ Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
¹⁷ Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
¹⁸ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.

PMID: 39302559
PMCID: PMC11489219
DOI: 10.1007/s12282-024-01632-z

Published Erratum

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Takahiro Nakayama et al. Breast Cancer. 2024 Nov.

. 2024 Nov;31(6):1184.

doi: 10.1007/s12282-024-01632-z.

Authors

Affiliations

¹ Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
² Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.
³ Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
⁴ Department of Breast Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
⁵ Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
⁶ Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
⁷ Department of Breast Surgery, Kitano Hospital, Osaka, Japan.
⁸ First Department of Surgery, University of the Ryukyus Hospital, Okinawa, Japan.
⁹ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
¹⁰ Department of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
¹¹ Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
¹² Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
¹³ Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
¹⁴ Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan.
¹⁵ Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
¹⁶ Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
¹⁷ Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
¹⁸ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.

PMID: 39302559
PMCID: PMC11489219
DOI: 10.1007/s12282-024-01632-z

No abstract available

PubMed Disclaimer

Erratum for

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, Takahara S, Nomura H, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Takiguchi D, Takata T, Bastanfard A, Shiosakai K, Tsurutani J. Nakayama T, et al. Breast Cancer. 2024 Nov;31(6):1167-1175. doi: 10.1007/s12282-024-01614-1. Epub 2024 Aug 12. Breast Cancer. 2024. PMID: 39133378 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Affiliations

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous